EUCTR2007-005054-23-IT进行中（未招募）不适用
A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF 1g, 2g, AND 4 g V0251 EFFICACY AND TOLERANCE IN VESTIBULAR NEURITIS - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient aged above 18 years, - Patient admitted to the hospital for vertigo related to acute vestibular neuritis, - Vestibular neuritis (acute unilateral vestibulopathy) defined as : acute or subacute onset of severe, prolonged rotatory vertigo, nausea and postural imbalance that began less than 48h before the inclusion visit, horizontal spontaneous nystagmus with a rotational component beating toward the unaffected ear (fast phase), without evidence of central vestibular lesion, peak slow phase velocity during caloric irrigation with 30C warm and 44C hot water less than three degrees per second on the affected side for each irrigation ; with an asymetry between the two sides more than 25 percent according to Jongkees? s formula during the bithermal caloric test which will be performed 3 days after treatment (initiated at inclusion visit), - Negative pregnancy test at inclusion for woman of child bearing potential and using an efficient contraceptive (implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner related to note 3 of the CPMP/ICH/286/95, see appendix 17.5) for at least 2 months before the study and one month after the end of the study, - Patient accepting to participate to the study and able to understand and sign an approved Informed Consent Form, - Patient able to understand the protocol and to come to the control visits, - Patient who, in the judgement of the investigator is likely to be compliant during the study - Registered with a social security or health insurance system
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •* Criteria related to pathologies - Vestibular dysfunction before the acute onset of symptoms, - Acute, unilateral (same side as the affected ear) tinnitus during, or after the onset of vertigo, ¬- Acute hearing loss during, or after the onset of vertigo, - Central ocular motor dysfunction - Central vestibular dysfunction - Symptoms of cerebellar disorder - Symptoms of central neurological disorder - History or symptoms of vestibular migraine - Recent history of ear and/or head trauma, - Tympanic membrane perforation - Chronic otitis, * Criteria related to treatments - Patient with history of hypersensitivity to ace`tylleucine or excipients, - History of systemic or transtympanic administration of aminoglycosides or any other ototoxic substances, - More than one antivertigo drug oral or intravenous administration before inclusion visit, - Hypnotics, antidepressants, if prescription initiated or modified within the 3 previous months before inclusion visit, * Criteria related to the population - Medical history of major medical, psychiatric illness or surgery which, in the judgement of the investigator, puts them ?at risk? or is likely to modify their handling of the study drug, - Female who is pregnant or breast feeding or not using contraception, or planning to become pregnant, - Participation to an other clinical trial in the previous month or during the study, - Patient who, is not able to understand the information (for linguistic or psychiatric reasons) and to give informed consent, - Patient who, in the judgement of the investigator, is not likely to be compliant during the study, - Patient who has forfeited his/her freedom by administrative or legal decision, or who is under guardianship.
研究者
相似试验
招募中
2 期
TO STUDY EFFICACY AND SAFETY OF CAPSULE ARTHRELLA COMPARED WITH PLACEBO IN OSTEOARTHRITISCTRI/2015/03/005643Charak Pharma Pvt Ltd CPPL Mumbai60
进行中（未招募）
不适用
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF A COMBINATION OF GALANTAMINE (AN ACETYLCHOLINESTERASE INHIBITOR) PLUS TRIMIPRAMINE IN SMOKING CESSATION - Smoking Cessation StudyHealthy subjects who are smokersEUCTR2004-001174-25-IEeurocure Ltd109
进行中（未招募）
1 期
To study the effectiveness and safety of REN001 in PMM patients after 24 weeks of treatmentPrimary Mitochondrial MyopathyMedDRA version: 20.0Level: PTClassification code 10027710Term: Mitochondrial myopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-002855-40-ITReneo Pharma LTD200
进行中（未招募）
1 期
To study the effectiveness and safety of REN001 in PMM patients after 24 weeks of treatment.Primary Mitochondrial MyopathyMedDRA version: 20.0Level: PTClassification code 10027710Term: Mitochondrial myopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-002855-40-ESReneo Pharma Ltd.200
进行中（未招募）
1 期
To study the effectiveness and safety of REN001 in PMM patients after 24 weeks of treatmentPrimary Mitochondrial MyopathyMedDRA version: 20.0Level: PTClassification code 10027710Term: Mitochondrial myopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-002855-40-NOReneo Pharma Ltd.200